Multi-source biosimilar competition in Europe to Roche’s Avastin (bevacizumab) that debuted last year led sales of the oncology biologic to nosedive by 68% to CHF138m ($151m) in the first-quarter of 2021, as Roche management conceded that “most of the Avastin business in Europe is now gone.”
Roche: Most Of Avastin Business In Europe Is Now Gone
Follows Competition From Biosimilar Bevacizumab Since Last Summer
Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.
More from Biosimilars
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.